info@sprs-therapy.ru

Close

Human Stem Cells Institute OJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine.

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank, as well as the reproductive cell and tissue bank Reprobank (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant project to create its own Russia-wide network of Genetico medical centers & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD and NIPT among others).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

www.eng.hsci.ru

OUR TEAM

The heads (and the main developers of the SPRS therapy)

Vadim Zorin

Candidate of Sciences in Biology. Head of the Department of Regenerative Medicine at the Human Stem Cells Institute, Russia (PJSC "HSCI"). The main developer of the technology based on the use of autologous skin fibroblasts to correct the age-related skin changes and scars (the SPRS^® therapy). The developer of two medical technologies, the author of 6 patents and more than 60 research papers and publications. The lecturer at the Department of Esthetic and Reconstructive Surgery, Cosmetology and Cell Technologies (Russian State Medical University). Associate Professor ar Department of Esthetic Medicine at RUDN University.

Alla Zorina

Candidate of Sciences in Medicine. The chief specialist (the Human Stem Cells Institute) on the interaction with clinics to introduce cell technologies into medical practice. The main developer of technology based on the use of autologous skin fibroblasts to correct the age-related skin changes and scars (the SPRS^® therapy). The developer of two medical technologies, the author of 10 patents and more than 60 research papers and publications. The lecturer at the Department of Dermatovenerology, Mycology, and Cosmetology (the Russian Medical Academy of Postgraduate Education).

Research and Production Complex

Galina Shilova

Head of the production complex,

Biotechnologist

Marina Malysheva

Candidate of Sciences in Biology,

Biotechnologist

Olga Kabanova

Biotechnologist

Sergey Kantserov, M.Sc.

Director, International Business Development

Marianna Lazakovich

Head of Clinic Relations Department

Svetlana Bogdanova

Manager, Clinic Relations Department

Ksenia Tokareva

Administrator

Grigory Terentev

IT Support